ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Mounjaro (tirzepatide by Year
Mounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M) ($M)
Eli Lilly Mounjaro (tirzepatide: $22,965M in FY2025, up 99.0% from a year earlier.
Where the FY2025 figure comes from
“|| Mounjaro | $ | 13,651 | $ | 9,315 | $ | 22,965 | $ | 11,540 | 99”
Source: Form 10-K FY2025 (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K Note 2, MD&A & Form 8-K Earnings Releases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Mounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22,965 | +99.0% | Form 10-K FY2025 (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 11,540 | +123.5% | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 5,163 | +970.1% | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 483 | – | Form 10-K FY2022 (filed 2023-02-22) ↗ |
Breakdown
What makes up mounjaro (tirzepatide
Cite this data
StockData. (2026). Eli Lilly Mounjaro (tirzepatide ($M), annual FY2022–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-mounjaro-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.